Search Results

You are looking at 61 - 70 of 444 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

-agent tivozanib in patients with platinum-resistant ovarian cancer Contact: Nikki Neubauer, MD • 312-472-4684 Rachel Bers, BS • 312-472-5726 • r-bers@northwestern.edu ClinicalTrials.gov Identifier: NCT01853644 Phase I Trial of Intraperitoneal Nab-Paclitaxel

Full access

F. Anthony Greco

Med 2004 ; 350 : 2335 – 2342 . 4. Sandler AB Gray R Perry MC . Paclitaxel-carboplatin alone or with bevacizumab for non-small lung cancer . N Engl J Med 2006 ; 355 : 2542 – 2550 . 5. Moore MJ Goldstein D Hamm J . Erlotinib

Full access

Athanassios Argiris

-fluoruracil (F) versus P, F and paclitaxel (T) as induction therapy in locally advanced head & neck cancer (LAHNC) (Abstr) . Proc Am Soc Clin Oncol 2003 ; 22 : A1997 . 8 Vermorken JB Remenar E Van Herpen C . Standard cisplatin/infusional 5

Full access

Leora Horn

in Oncology (NCCN Guidelines) for NSCLC, many chemotherapy drugs are useful for treating patients with advanced-stage NSCLC. Among them are platinum agents (eg, cisplatin, carboplatin), taxanes (eg, paclitaxel, albumin-bound paclitaxel, docetaxel

Full access

Maurie Markman

: 4265 – 4269 . 16 Francis P Rowinsky E Schneider J . Phase 1 feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study . J Clin Oncol 1995 ; 13 : 2961 – 2967 . 17 Markman

Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Warner K. Huh, John R. Lurain III, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

single agents in the metastatic disease setting based on several randomized phase III trials. 18 , 19 Cisplatin is a standard backbone of combination chemotherapy regimens, and cisplatin-based chemotherapy regimens (eg, cisplatin/paclitaxel

Full access

Matthieu Picard, Ursula A. Matulonis, and Mariana Castells

doxorubicin (PLD) seems to significantly reduce the incidence of HSRs attributable to carboplatin compared with administering carboplatin as a single agent or in combination with paclitaxel. 31 , 32 The effect of PLD on reducing carboplatin-related infusion

Full access

Neelima Vidula, Leif W. Ellisen, and Aditya Bardia

III study compared veliparib with carboplatin and paclitaxel followed by maintenance veliparib versus chemotherapy in germline BRCA1/2 -mutant HER2-negative advanced breast cancer. 18 Median PFS improved from 12.6 to 14.5 months with the addition of

Full access

Dipesh Uprety and David E. Marinier

used for concurrent CRT, including cisplatin/etoposide, carboplatin/paclitaxel, cisplatin/vinblastine, and, for nonsquamous pathology, carboplatin or cisplatin with pemetrexed. 7 The carboplatin/paclitaxel regimen is given weekly with radiation therapy

Full access

Presenters: Melinda L. Telli and William J. Gradishar

1mic disease. 3 Treatment with weekly paclitaxel for 12 cycles plus trastuzumab for 1 year led to a 7-year OS rate of 95%, with only 4 of 406 patients experiencing distant recurrences. The subsequent ATEMPT trial evaluated the newer agent ado